Synergistic effects of pemetrexed and amrubicin in non-small cell lung cancer cell lines: Potential for combination therapy

Cancer Letters

Volumn 343, Issue 1, 2014, Pages 74-79

  Hatakeyama, Yukihisa ^a   Kobayashi, Kazuyuki ^a   Nagano, Tatsuya ^a   Tamura, Daisuke ^a   Yamamoto, Masatsugu ^a   Tachihara, Motoko ^a   Kotani, Yoshikazu ^a   Nishimura, Yoshihiro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Amrubicin; Non small cell lung cancer; Pemetrexed; Thymidylate synthase

Indexed keywords

AMRUBICIN; DIHYDROFOLATE REDUCTASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; THYMIDYLATE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

MUS;

EID: 84890858182     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.09.019     Document Type: Article

References (16)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: Cancer J. Clinicians 2011, 61:69-90.
2. Stinchcombe T.E., Lee C.B., Socinski M.A. Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status. Clin. Lung Cancer 2006, 7(Suppl 4):S111-117.
3. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346:92-98.
4. Goldstraw P., Ball D., Jett J.R., Le Chevalier T., Lim E., Nicholson A.G., Shepherd F.A. Non-small-cell lung cancer. Lancet 2011, 378:1727-1740.
5. Danenberg P.V., Malli H., Swenson S. Thymidylate synthase inhibitors. Semin. Oncol. 1999, 26:621-631.
6. Costi M.P., Ferrari S., Venturelli A., Calo S., Tondi D., Barlocco D. Thymidylate synthase structure, function and implication in drug discovery. Curr. Med. Chem. 2005, 12:2241-2258.
7. Sigmond J., Backus H.H., Wouters D., Temmink O.H., Jansen G., Peters G.J. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase over expression. Biochem. Pharm. 2003, 66:431-438.
8. Shih C., Chen V.J., Gossett L.S., Gates S.B., MacKellar W.C., Habeck L.L., Shackelford K.A., Mendelsohn L.G., Soose D.J., Patel V.F., Andis S.L., Bewley J.R., Rayl E.A., Moroson B.A., Beardsley G.P., Kohler W., Ratnam M., Schultz R.M. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997, 57:1116-1123.
9. Azrak R.G., Cao S., Slocum H.K., Toth K., Durrani F.A., Yin M.B., Pendyala L., Zhang W., McLeod H.L., Rustum Y.M. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin. Cancer Res.: An official J. Am. Assoc. Cancer Res. 2004, 10:1121-1129.
10. Takiuchi H., Kawabe S., Gotoh M., Katsu K. Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer. Gastrointest. Cancer Res. 2007, 1:171-176.
11. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
12. Nagano T., Yasunaga M., Goto K., Kenmotsu H., Koga Y., Kuroda J., Nishimura Y., Sugino T., Nishiwaki Y., Matsumura Y. Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer. Int. J. Cancer J. Int. du Cancer 2010, 127:2699-2706.
13. Ceppi P., Volante M., Saviozzi S., Rapa I., Novello S., Cambieri A., Lo Iacono M., Cappia S., Papotti M., Scagliotti G.V. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107:1589-1596.
14. Righi L., Papotti M.G., Ceppi P., Bille A., Bacillo E., Molinaro L., Ruffini E., Scagliotti G.V., Selvaggi G. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010, 28:1534-1539.
15. Seiler J.A., Conti C., Syed A., Aladjem M.I., Pommier Y. The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol. Cell. Biol. 2007, 27:5806-5818.
16. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., Serwatowski P., Gatzemeier U., Digumarti R., Zukin M., Lee J.S., Mellemgaard A., Park K., Patil S., Rolski J., Goksel T., de Marinis F., Simms L., Sugarman K.P., Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008, 26:3543-3551.